More than 250 prescription drugs will have price increases, according to a Reuters report. The news agency says that during a White House meeting with members of his Cabinet, U.S. President Donald Trump on Wednesday said he expected to see a tremendous decrease in drug prices.
The overall number of price increases was down by around a third from last year, when drugmakers raised prices on more than 400 medicines, according to data provided by Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines.
PFE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on February 19, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for PFE moved out of overbought territory on January 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on March 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on February 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 211 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.750) is normal, around the industry mean (9.384). P/E Ratio (19.574) is within average values for comparable stocks, (22.964). PFE's Projected Growth (PEG Ratio) (13.773) is very high in comparison to the industry average of (2.286). PFE's Dividend Yield (0.065) is considerably higher than the industry average of (0.025). P/S Ratio (2.430) is also within normal values, averaging (3.967).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor